Ignite Creation Date:
2024-05-06 @ 12:49 PM
Last Modification Date:
2024-10-26 @ 1:04 PM
Study NCT ID:
NCT03854227
Status:
TERMINATED
Last Update Posted:
2022-11-22
First Post:
2019-02-15
Brief Title:
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06939999 PRMT5 INHIBITOR IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA ESOPHAGEAL CANCER ENDOMETRIAL CANCER CERVICAL CANCER AND BLADDER CANCER
Status:
TERMINATED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study has been terminated based on a strategic evaluation within the current Pfizer oncology portfolio This decision is not due to any safety concerns or requests from any regulatory authorities
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 open label multi center dose escalation and expansion safety tolerability PK and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None